Cosciens Biopharma rugi bersih Q2 FY26 menyempit jadi US$ 0,2 juta; revenue naik 29,17% jadi US$ 3,1 juta

Reuters2026/08/11 21:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Cosciens Biopharma mencatat rugi bersih kuartal II 2026 menyempit menjadi US$ 0,2 juta, atau US$ 0,19 per saham.
Revenue naik 29,17% menjadi US$ 3,1 juta, didorong volume penjualan yang lebih tinggi.
Beban operasi turun 50% menjadi US$ 1,3 juta, seiring penurunan biaya SG&A dan riset-pengembangan.
Semester I 2026 berbalik ke laba bersih US$ 10,6 juta, atau US$ 10,08 per saham, dibantu dekonsoolidasi unit Jerman.
Kas dan setara kas tercatat US$ 5,3 juta; CEO Peter Puccetti menyoroti fokus mendukung target pertumbuhan Ceapro dan mencari peluang skala.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosciens Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608111730PRIMZONEFULLFEED9808024) on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Cosciens Biopharma rugi bersih Q2 FY26 menyempit jadi US$ 0,2 juta; revenue naik 29,17% jadi US$ 3,1 juta

You may also like

Crypto prices